Analysis of risk factors of liver injury after intravenous methylprednisolone in neuromyelitis optica spectrum disorders

doi:10.3969/j.issn.1672-6731.2022.09.004

Abstract

Abstract: Objective To investigate the risk factors of liver injury in patients with neuromyelitis optica spectrum disorders (NMOSDs) after intravenous methylprednisolone (IVMP). Methods A total of 195 patients with NMOSDs who received IVMP in Beijing Tongren Hospital, Capital Medical University from January 2017 to December 2021 were enrolled. The causal relationship between IVMP and liver injury was evaluated according to Roussel Uclaf Causality Assessment Method (RUCAM). Univariate and multivariate stepwise Logistic regression analysis were used to screen the risk factors of IVMP related liver injury. Results Within 14 d after IVMP therapy, 32.31% (63/195) patients developed liver injury[serum alanine aminotransferase (ALT) > 40 U/L, RUCAM score ≥ 3]. Severe injury (ALT > 120 U/L) accounted for 15.87% (10/63) and mild injury 84.13% (53/63). Logistic regression analysis showed age ≥ 50 years old (OR=0.969, 95%CI:0.945-0.993; P=0.011), previous use of immunosuppressants (OR=3.543, 95%CI:1.579-7.949; P=0.002) and history of IVMP related liver injury (OR=17.043, 95%CI:3.400-85.423; P=0.000) were the main risk factors for IVMP related liver injury. Conclusions The main IVMP related liver injury is mild injury. NMOSDs patients aged ≥ 50 years old, previous use of immunosuppressants and history of IVMP related liver injury are more prone to liver injury when treated with IVMP again.

Key words: Neuromyelitis optica, Methylprednisolone, Chemical and drug induced liver injury, Risk factors, Logistic models

摘要： 目的筛查视神经脊髓炎谱系疾病（NMOSDs）患者静脉注射甲泼尼龙（IVMP）诱发肝损伤危险因素。方法回顾分析2017年1月至2021年12月在首都医科大学附属北京同仁医院行IVMP冲击治疗的195例NMOSDs患者临床资料，根据Roussel Uclaf因果关系评估法（RUCAM）评估IVMP与肝损伤间的因果关系，单因素和多因素逐步法Logistic回归分析筛查IVMP相关肝损伤的危险因素。结果 IVMP冲击治疗后14 d内，血清肝酶谱检测约32.31%（63/195）患者发生肝损伤[血清丙氨酸转氨酶（ALT）> 40 U/L，RUCAM评分 ≥ 3分]，重度肝损伤（ALT > 120 U/L）占15.87%（10/63）、轻度肝损伤占84.13%（53/63）。Logistic回归分析显示，年龄 ≥ 50岁（OR=0.969，95% CI：0.945~0.993；P=0.011）、免疫抑制剂应用史（OR=3.543，95% CI：1.579~7.949；P=0.002）和IVMP相关肝损伤史（OR=17.043，95% CI：3.400~85.423；P=0.000）是IVMP相关肝损伤的危险因素。结论 IVMP相关肝损伤以轻度肝损伤为主，年龄 ≥ 50岁、有免疫抑制剂应用史和IVMP相关肝损伤史的NMOSDs患者再次行IVMP冲击治疗易发生肝损伤。

关键词: 视神经脊髓炎, 甲泼尼龙, 化学性与药物性肝损伤, 危险因素, Logistic模型

YANG Qing-lin, LIU Peng-peng, WANG Jia-wei. Analysis of risk factors of liver injury after intravenous methylprednisolone in neuromyelitis optica spectrum disorders[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(9): 764-769.

杨庆林, 刘朋朋, 王佳伟. 视神经脊髓炎谱系疾病静脉注射甲泼尼龙后肝损伤危险因素分析[J]. 中国现代神经疾病杂志, 2022, 22(9): 764-769.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2022.09.004

https://journal11.magtechjournal.com/cjcnn/EN/Y2022/V22/I9/764

References

[1] Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology, 2015, 85:177-189.
[2] Neuroimmunology Branch, Chinese Society of Immunology.Chinese guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders (2021 edition)[J].Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28:423-436.[中国免疫学会神经免疫分会.中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J].中国神经免疫学和神经病学杂志, 2021, 28:423-436.]
[3] Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lönnqvist F, Gaillard P.Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment:a prospective web-based multi-center study in multiple sclerosis patients with a relapse[J].J Neurol, 2016, 263:1641-1651.
[4] Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida K, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira J.Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica[J].Mult Scler, 2016, 22:1337-1348.
[5] Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, Apostolos-Pereira SL, Martynenko Y, Breu M, de Medeiros Rimkus C, Wassmer E, Baumann M, Papetti L, Capobianco M, Kornek B, Rostásy K, da Paz JA, Ciccarelli O, Lim M, Saiz A, Neuteboom R, Marignier R, Hemingway C, Sato DK, Deiva K.Treatment and outcome of aquaporin-4 antibody-positive NMOSD:a multinational pediatric study[J].Neurol Neuroimmunol Neuroinflamm, 2020, 7:e837.
[6] Pharmaceutical Hepatology Group, Hepatology Branch, Chinese Medical Association.Diagnosis and treatment guideline on drug-induced liver injury[J].Zhonghua Gan Zang Bing Za Zhi, 2015, 23:810-820.[中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23:810-820.]
[7] Danan G, Benichou C.Causality assessment of adverse reactions to drugs:Ⅰ.A novel method based on the conclusions of international consensus meetings:application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46:1323-1330.
[8] Li L, Jiang W, Wang J.Clinical analysis of 275 cases of acute drug-induced liver disease[J].Front Med China, 2007, 1:58-61.
[9] Zoubek ME, Pinazo-Bandera J, Ortega-Alonso A, Hernández N, Crespo J, Contreras F, Medina-Cáliz I, Sanabria-Cabrera J, Sanjuan-Jiménez R, González-Jiménez A, García-Cortés M, Lucena MI, Andrade RJ, Robles-Díaz M.Liver injury after methylprednisolone pulses:a disputable cause of hepatotoxicity.A case series and literature review[J].United European Gastroenterol J, 2019, 7:825-837.
[10] Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, Vukusic S, Vial T.Methylprednisolone liver toxicity:a new case and a French regional pharmacovigilance survey[J].Clin Res Hepatol Gastroenterol, 2017, 41:497-501.
[11] Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, Marrone G, Grieco A, Mirabella M.Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients[J].Brain Behav, 2018, 8:e00968.
[12] Eguchi H, Tani J, Hirao S, Tsuruta M, Tokubuchi I, Yamada K, Kasaoka M, Teshima Y, Kakuma T, Hiromatsu Y.Liver dysfunction associated with intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy[J].Int J Endocrinol, 2015:ID835979.
[13] Kimura H, Takeda A, Kikukawa T, Hasegawa I, Mino T, Uchida-Kobayashi S, Ohsawa M, Itoh Y.Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis[J].Mult Scler Relat Disord, 2020, 42:102065.
[14] Padda MS, Sanchez M, Akhtar AJ, Boyer JL.Drug-induced cholestasis[J].Hepatology, 2011, 53:1377-1387.
[15] Sha J, Aishanjiang Y, Mayinuer M, Li HY.Recurrent myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis-encephalomyelitis:one case report[J].Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2020, 20:877-880.[沙晶, 艾山江·玉素甫江, 玛依努尔·买买提, 李红燕.复发性抗MOG抗体相关性视神经炎-脑脊髓炎一例[J].中国现代神经疾病杂志, 2020, 20:877-880.]
[16] Du M, Jiang ZZ, Zhang LY.Research progress on liver injury caused by commonly used immunosuppressants[J].Yao Wu Ping Jia Yan Jiu, 2022, 45:982-988.[杜敏, 江振洲, 张陆勇.常用免疫抑制剂致肝损伤的研究进展[J].药物评价研究, 2022, 45:982-988.]
[17] Mehendale HM.Tissue repair:an important determinant of final outcome of toxicant-induced injury[J].Toxicol Pathol, 2005, 33:41-51.
[18] Hassan A, Fontana RJ.The diagnosis and management of idiosyncratic drug-induced liver injury[J].Liver Int, 2019, 39:31-41.

Please choose a citation manager

Content to export